Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy With Metronomic/Oral Chemotherapy (Cytophosphan Combined With Low-dose Methotrexate)and COX-2 Inhibition (Celecoxib)
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Time to Progression
Median time to progression of the cohort will be compared with equivalent measure in the literature.
David Loven, M.D.
HaEmek Medical Center, Oncology Unit
Israel: Israeli Health Ministry Pharmaceutical Administration